DOI:

Comparison of new EuroSCORE II with logistic EuroSCORE and STS score in predicting 30-day and one-year mortality in patients undergoing TAVI

Hashmi I., Rajagopal R., Gardezi S., Wojciuk J., More R., Rogers S., Tassiker J., Tang A., Sogliani F., Roberts D.

Risk assesment in TAVI including valve-in-valve

Comparison of new EuroSCORE II with logistic EuroSCORE and STS score in predicting 30-day and one-year mortality in patients undergoing TAVI

Aims: The validity of the logistic EuroSCORE (LES) and STS score for risk stratification in patients undergoing TAVI is questionable. The purpose of this study was to compare the newly created EuroSCORE II (ES II) with the LES and STS score in patients undergoing TAVI by Medtronic CoreValve or Edwards SAPIEN after formal turn-down for surgical AVR.

Methods and results: Eighty-two consecutive patients in a single institution underwent TAVI via the transfemoral, trans-subclavian, transapical and direct aortic approaches. Estimated LES, ES II and STS score were calculated retrospectively. The 30-day mortality was 7.3% (6/82) and the one-year mortality was 23.2% (19/82). The mean LES of patients who did not survive at 30 days was 33% and among survivors it was 23.5% (p=0.8; RR 1.4, 95% CI 0.44-4.46). The ES II at 30 days was 20.1% in non-survivors and 10.3% in survivors (p=0.62, RR 1.96, 95% CI 0.61 - 6.32). The STS score was 9.1% and 7.6% (p=0.87; RR 1.2, 95% CI 0.5-2.89) in non-survivors and survivors respectively. At one-year, the mean LES in non-survivors was 28.2% and 22.9% in survivors (p=0.84; RR 1.23, 95% CI 0.51-3.0). ES II was 13.9% and 10.2% (p=0.79; RR 1.36, 95% CI 0.5-3.71). The STS score was 8% and 7.6% (p=0.95; RR 1.05, 95% CI 0.52-2.14). Overall there was no difference in the relative risk between the non-survivors and survivors based on any of the three risk scores. We then classified the patients into low, intermediate and high risk groups (LES <10, 10-20, >20%, ES II <5, 5-10, >10% and STS <5, 5-10, >10% respectively) and analysed the 30-day and one-year mortality. Patients in the high ES II risk group (>10%) had higher mortality compared with both low-risk and intermediate-risk groups at 30 days and one year following TAVI, although this failed to reach statistical significance. In contrast the LES and STS score did not show any consistent trends among the three risk groups.

Conclusions: ES II was no better than LES or STS score in predicting 30-day or one-year mortality in patients undergoing TAVI after formal surgical turn-down. ES II may predict mortality better in the highest risk group. This study highlights the deficiencies of all three surgical risk scores in predicting mortality in patients undergoing TAVI and thus the need to develop a dedicated TAVI risk score system.

Volume 8 Supplement Q
Sep 30, 2012
Volume 8 Supplement Q
View full issue


Key metrics

Suggested by Cory

CLINICAL RESEARCH

10.4244/EIJ-D-17-00421 Jan 19, 2018
TAVI risk scoring using established versus new scoring systems: role of the new STS/ACC model
Arsalan M et al
free

10.4244/EIJV13I13A241 Jan 19, 2018
The business of risk
Lennon R and Holmes D
free

10.4244/EIJV11SWA6 Sep 17, 2015
Measuring risk in valvular interventions: from low risk to futility
Kappetein A
free
Trending articles
152.9

Clinical research

10.4244/EIJ-D-20-01125 Oct 20, 2021
An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation
Costa G et al
free
47.8

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
39.1

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
38.95

State-of-the-Art

10.4244/EIJ-D-23-00912 Oct 7, 2024
Optical coherence tomography to guide percutaneous coronary intervention
Almajid F et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved